Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 8 Next >
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the 26th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Streamlined Clinical Alignment
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Host Virtual R&D Day on February 28, 2023
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Highlights 2022 Accomplishments and Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin’s EMBARK Program Announces Graduation of Facilitators
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin & The Chopra Foundation Recognize World Mental Health Day
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Update on its Intellectual Property Portfolio
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in Upcoming Scientific and Investor Conferences
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Final Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.